Mechanism of action
Olanzapine is a thienobenzodiazepine derivative that exerts its antipsychotic effects through antagonism at multiple receptor sites. The therapeutic efficacy in psychosis is attributed to blockade of dopamine D2 receptors in the mesolimbic pathway, reducing positive symptoms, and serotonin 5-HT2A receptor antagonism, which may improve negative and cognitive symptoms while reducing extrapyramidal side effects compared to first-generation antipsychotics.
Olanzapine has high affinity for multiple receptors:
- D1, D2, D3, D4 receptors: antipsychotic effect, but also motor and endocrine effects
- 5-HT2A, 5-HT2C, 5-HT3, 5-HT6 receptors: mood stabilization, reduced EPS risk, but weight gain (5-HT2C)
- Muscarinic M1-M5 receptors: anticholinergic side effects (dry mouth, constipation, cognitive effects)
- Histamine H1 receptors: sedation and significant weight gain
- Alpha-1 adrenergic receptors: orthostatic hypotension
The broad receptor profile explains both the efficacy across symptom domains and the extensive side effect profile, particularly metabolic disturbances.
- Olanzapine has the highest risk of weight gain and metabolic syndrome among atypical antipsychotics (along with clozapine).
- Metabolized primarily by CYP1A2; smoking induces CYP1A2 and lowers olanzapine levels by ~40%, requiring higher doses in smokers.
- Black box warning: increased mortality in elderly patients with dementia-related psychosis (cardiovascular and infectious deaths).
- Olanzapine blocks D2, 5-HT2A, H1, M1, and alpha-1 receptors, explaining its broad side effect profile including sedation and orthostatic hypotension.
- Lower risk of extrapyramidal symptoms compared to first-generation antipsychotics and risperidone due to high 5-HT2A/D2 ratio.
- Approved for schizophrenia, bipolar mania, bipolar maintenance, and treatment-resistant depression (with fluoxetine).
- Monitor fasting glucose, HbA1c, lipids, and weight at baseline, 12 weeks, then annually due to high metabolic risk.
- Long half-life (~30 hours) allows once-daily dosing; steady state reached in approximately one week.
Indications
Olanzapine is approved for:
Psychiatric indications:
- Schizophrenia: treatment of acute psychotic episodes and maintenance therapy
- Bipolar I disorder: acute treatment of manic or mixed episodes (monotherapy or with lithium/valproate)
- Bipolar disorder maintenance: prevention of relapse in bipolar I disorder
- Treatment-resistant depression: in combination with fluoxetine (as Symbyax)
- Agitation: acute intramuscular injection for agitation associated with schizophrenia or bipolar mania
Off-label uses:
- Delirium in hospitalized patients
- Chemotherapy-induced nausea and vomiting (refractory cases)
- Anorexia nervosa
- Behavioral disturbances in dementia (use with extreme caution due to increased mortality risk)
Olanzapine is often chosen when sedation is desired or when a patient has failed other atypical antipsychotics, despite its metabolic risks.
Pharmacokinetics
Absorption: Well absorbed orally, with peak plasma concentrations in 5-8 hours. Food does not significantly affect absorption. Bioavailability is approximately 60% due to first-pass metabolism.
Distribution: Highly protein-bound (93%), primarily to albumin and alpha-1-acid glycoprotein. Volume of distribution is extensive (approximately 1000 L), indicating significant tissue distribution.
Metabolism: Extensively metabolized in the liver via direct glucuronidation and cytochrome P450-mediated oxidation, primarily by CYP1A2 (major pathway, ~40%) and CYP2D6 (minor pathway). The 10-N-glucuronide is the major circulating metabolite but is inactive. Smoking induces CYP1A2 and increases olanzapine clearance by approximately 40%.
Elimination: Half-life ranges from 21-54 hours (average 30 hours), allowing once-daily dosing. Approximately 57% is excreted in urine (primarily as metabolites) and 30% in feces. Less than 10% is excreted unchanged.
Special populations: Clearance is reduced in females, elderly patients, and those with hepatic impairment. Dosage adjustments may be necessary in these populations.
Adverse effects
Olanzapine has a significant side effect burden, particularly metabolic effects.
Common adverse effects
- Metabolic effects (most clinically significant):
- Weight gain: occurs in >50% of patients, often substantial (>7% baseline weight)
- Hyperglycemia: new-onset diabetes mellitus or diabetic ketoacidosis, even without weight gain
- Dyslipidemia: elevated triglycerides and LDL cholesterol
- Metabolic syndrome: combination of above increases cardiovascular risk
- Sedation/somnolence: very common, especially early in treatment
- Anticholinergic effects: dry mouth, constipation, urinary retention, blurred vision
- Orthostatic hypotension: due to alpha-1 blockade, especially with parenteral administration
- Increased appetite: contributes to weight gain
- Dizziness
- Akathisia: less common than with first-generation antipsychotics but can occur
Serious adverse effects
- Hyperglycemia and diabetes mellitus: can be severe; monitor fasting glucose and HbA1c
- Hyperlipidemia: monitor lipid panel regularly
- Neuroleptic malignant syndrome (NMS): rare but life-threatening; fever, rigidity, altered mental status, autonomic instability
- Tardive dyskinesia: involuntary movements, risk increases with duration of use
- Seizures: dose-related, occurs in ~0.9% of patients
- Orthostatic hypotension with syncope: especially in elderly
- Leukopenia, neutropenia, agranulocytosis: monitor CBC if signs of infection
- Hyperprolactinemia: less common than with first-generation antipsychotics or risperidone, but can occur
Black box warnings
- Increased mortality in elderly patients with dementia-related psychosis: primarily from cardiovascular events or infections; olanzapine is not approved for this indication
Extrapyramidal symptoms
Olanzapine has a lower risk of EPS compared to first-generation antipsychotics and some other atypical agents (like risperidone), but EPS can still occur, particularly at higher doses.
Contraindications and warnings
Absolute contraindications:
- Hypersensitivity to olanzapine or any formulation component
Warnings and precautions:
- Metabolic monitoring is essential: baseline and periodic monitoring of weight, BMI, waist circumference, fasting glucose, HbA1c, and lipid panel (at baseline, 12 weeks, then annually or more frequently if abnormal)
- Cardiovascular disease: use with caution due to risk of orthostatic hypotension and QTc prolongation (though less than some other antipsychotics)
- Cerebrovascular events: increased risk of stroke in elderly patients with dementia
- Seizure disorder: lowers seizure threshold; use cautiously in patients with history of seizures
- Hepatic impairment: use with caution and consider lower starting dose; monitor liver function tests
- Prostatic hypertrophy or narrow-angle glaucoma: anticholinergic effects may exacerbate these conditions
- Paralytic ileus: risk due to anticholinergic effects
- Pregnancy: category C; neonates exposed in third trimester may experience extrapyramidal and/or withdrawal symptoms; use only if benefit outweighs risk
- Breastfeeding: olanzapine is excreted in breast milk; discuss risks/benefits
- Hypotension risk: particularly with IM administration; patient should remain recumbent if drowsy or dizzy
- Body temperature regulation: may impair ability to reduce core body temperature; caution in hot environments
Drug-specific risks:
- Risk of diabetic ketoacidosis and hyperosmolar coma has been reported, sometimes in patients without prior diabetes diagnosis
- Monitor for signs of hyperglycemia: polyuria, polydipsia, polyphagia, weakness
Drug interactions
Olanzapine undergoes extensive hepatic metabolism, leading to multiple clinically significant drug interactions.
Pharmacokinetic interactions
CYP1A2 interactions:
- Fluvoxamine (strong CYP1A2 inhibitor): increases olanzapine concentrations significantly; reduce olanzapine dose
- Ciprofloxacin (moderate CYP1A2 inhibitor): may increase olanzapine levels
- Cigarette smoking (CYP1A2 inducer): increases olanzapine clearance by ~40%; smokers may require higher doses; dose reduction needed if patient quits smoking
- Carbamazepine, rifampin (CYP inducers): increase olanzapine clearance, reducing efficacy
Pharmacodynamic interactions
- CNS depressants (benzodiazepines, opioids, alcohol): additive sedation and respiratory depression; use cautiously, especially with parenteral olanzapine and parenteral benzodiazepines (risk of excessive sedation, bradycardia, respiratory depression)
- Anticholinergic agents: additive anticholinergic effects (confusion, constipation, urinary retention, heat intolerance)
- Antihypertensives: additive hypotensive effects due to alpha-1 blockade
- Levodopa and dopamine agonists: olanzapine may antagonize their effects
- QTc-prolonging drugs: additive QTc prolongation risk, though olanzapine itself has modest QTc effects
Other considerations
- Alcohol: should be avoided due to additive CNS depression
- Activated charcoal: if given for overdose, may reduce olanzapine absorption
Clinical pearls
- Highest metabolic risk among atypicals: olanzapine and clozapine have the greatest propensity for weight gain, diabetes, and dyslipidemia. Always weigh metabolic risk against efficacy benefits.
- First-line in acute mania: olanzapine is highly effective for acute manic episodes and is often preferred when rapid sedation is needed.
- Long-acting injectable (LAI) formulation: olanzapine pamoate is available for maintenance treatment in schizophrenia but requires post-injection observation for 3 hours due to risk of post-injection delirium/sedation syndrome.
- Combination with fluoxetine: the olanzapine-fluoxetine combination is FDA-approved for treatment-resistant depression and acute bipolar depression. The combination is synergistic.
- Smoking cessation matters: if a patient quits smoking while on olanzapine, levels can increase significantly (CYP1A2 induction reversal), potentially causing toxicity. Reduce dose by 30-50% if patient stops smoking.
- Monitor metabolic parameters aggressively: weight at every visit, fasting glucose and lipids at baseline, 12 weeks, then annually at minimum. Early intervention (diet, exercise, metformin) can mitigate metabolic effects.
- Lower EPS risk: olanzapine is a good choice when a patient has experienced significant EPS with other antipsychotics, though akathisia can still occur.
- Avoid in dementia patients: black box warning for increased mortality; reserve for cases where benefit clearly outweighs risk and document rationale.
- Overdose management: supportive care; no specific antidote. Monitor cardiac function and vital signs. Avoid epinephrine (may worsen hypotension due to beta-agonist effects in setting of alpha blockade).
- Pregnancy considerations: if used in pregnancy, inform patient of neonatal risks. Antipsychotic discontinuation must be weighed against risk of relapse, which itself poses fetal risk.
O-LANZapine metabolic risks: O = Obesity (weight gain), L = Lipids elevated, A = A1c increased (diabetes), NZ = eNZyme CYP1A2 (smoking interaction)
Practice questions
1. A 28-year-old man with schizophrenia has been maintained on olanzapine 15 mg daily for 9 months with good control of psychotic symptoms. He smoked one pack of cigarettes daily when treatment began. He now reports he quit smoking 2 weeks ago. Over the past week, he has experienced increased drowsiness, slurred speech, and difficulty walking. Physical examination shows ataxia and sedation. Vital signs are stable. Which of the following is the most likely explanation?
2. A 34-year-old woman with bipolar I disorder is started on olanzapine for an acute manic episode. At her 3-month follow-up, she reports her mood is stable, but she has gained 9 kg (20 lbs). Laboratory studies show fasting glucose 142 mg/dL (previously 92 mg/dL), triglycerides 310 mg/dL (previously 145 mg/dL), and HDL 38 mg/dL. Blood pressure is 118/76 mmHg, BMI has increased from 24 to 27 kg/m². Which of the following is the most appropriate next step?
3. A 72-year-old woman with Alzheimer dementia and severe agitation is brought to the clinic by her daughter. The patient has become increasingly combative, is not sleeping, and has struck nursing staff at her facility. The physician considers prescribing olanzapine for behavioral control. Which of the following represents the most significant risk associated with this treatment?
Frequently asked questions
How does olanzapine work?
Olanzapine works by blocking dopamine D2 receptors in the brain, which reduces psychotic symptoms like hallucinations and delusions, and serotonin 5-HT2A receptors, which may improve mood and reduce side effects. It also blocks histamine H1, muscarinic, and alpha-adrenergic receptors, contributing to its side effects including sedation, weight gain, dry mouth, and orthostatic hypotension. The combination of dopamine and serotonin blockade makes it an atypical (second-generation) antipsychotic.
What are the side effects of olanzapine?
The most common side effects are significant weight gain, increased appetite, sedation, and dry mouth. Olanzapine has the highest risk among atypical antipsychotics for causing metabolic syndrome, including new-onset diabetes, elevated cholesterol and triglycerides, and substantial weight gain. Other side effects include dizziness, constipation, orthostatic hypotension, and (rarely) movement disorders. Serious risks include neuroleptic malignant syndrome, seizures, and in elderly dementia patients, increased mortality.
Is olanzapine a controlled substance?
No, olanzapine is not a controlled substance under the DEA Controlled Substances Act. It is not considered to have abuse potential or physical dependence liability. However, it is a prescription medication that requires monitoring due to its significant side effect profile, particularly metabolic effects. It should be prescribed and monitored by a qualified healthcare provider.
Olanzapine vs quetiapine — what is the difference?
Both are atypical antipsychotics, but olanzapine has much higher risk of weight gain and metabolic syndrome, while quetiapine is more sedating and carries greater risk of orthostatic hypotension at therapeutic doses. Olanzapine is generally more potent for psychosis and mania, while quetiapine at lower doses is often used off-label for insomnia or anxiety due to strong H1 blockade. Quetiapine has a shorter half-life requiring twice-daily dosing (immediate-release), whereas olanzapine is dosed once daily.
What should be monitored when taking olanzapine?
Metabolic parameters must be monitored closely: weight and BMI at every visit, fasting blood glucose and HbA1c at baseline, 12 weeks, then annually, and lipid panel on the same schedule. Blood pressure should be checked regularly due to orthostatic hypotension risk. Patients should be assessed for signs of diabetes (increased thirst, urination, hunger), movement disorders, and sedation. Baseline and periodic monitoring for tardive dyskinesia using scales like AIMS is recommended with long-term use.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N05AH03
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.